Organ Replacement & Biofabrication

This field is about building or growing replacement body parts for cases where an organ is too damaged to repair. The work ranges from lab-grown tissues and organoids—simplified, miniature versions of organs grown from cells—to 3D-bioprinted structures.

Some age-related organ decline may ultimately be addressed by replacement rather than repair. Progress here could extend healthy lifespan in cases where regeneration or drugs on their own are not enough.

That would support the broader goal of Longevity Escape Velocity: reaching a point where advances across multiple medical fields extend healthy lifespan faster than time passes.

• Engineered tissue: Research on grown or constructed tissues and organoids.
• Bioprinting: Progress in printing techniques and materials for biological structures.
• Transplantation results: Preclinical and clinical transplantation using engineered tissue.
• Manufacturing: Scale-up progress for lab-grown tissue.

• Small-scale tissue samples with no functional or transplantation testing.
• Concept renderings or prototypes with no described biological result.
• Organ-transplant news unrelated to engineered or bioprinted tissue.

• Vascularization: Larger engineered tissues still need a working blood supply.
• Immune rejection: Engineered or donor tissue may be rejected by the immune system.
• Manufacturing: Consistency and cost remain difficult at scale.
• Regulation: Implantable engineered tissue faces long regulatory pathways.

Xenotransplantation has produced documented human clinical milestones, which is why this outscores geroscience drugs. But replacement is a repair strategy with a hard ceiling: it addresses discrete organ failure rather than systemic aging, and the brain is not replaceable. Whole-organ de-novo biofabrication remains far from clinic with vascularisation the standing obstacle, which caps the contribution below rejuvenation.

This readiness score is a published model input, not a measurement or clinical forecast. It summarizes the field under the assumptions documented in the model and does not predict that any specific intervention will succeed. It should be treated as an evolving assessment, not a guaranteed roadmap.